Porphyria Cutanea Tarda (PCT) Clinical Trials and Treatments

Porphyria cutanea tarda (PCT) is the most common porphyria, representing approximately 80% of all porphyria cases, characterized by deficiency of uroporphyrinogen decarboxylase (UROD), the fifth enzyme in the heme synthesis pathway. The UROD deficiency leads to accumulation of uroporphyrin and other porphyrin precursors predominantly in the liver and skin, driving the characteristic photosensitive cutaneous manifestations. Type I PCT (80% of cases) is acquired without UROD gene mutations, usually triggered by hepatitis C infection, HIV infection, alcohol consumption, estrogen use, iron overload, or other factors that impair hepatic UROD enzyme activity.

The most common symptoms of Porphyria Cutanea Tarda include Fragile skin with blistering on sun-exposed areas, Hyperpigmentation and hypopigmentation, Hypertrichosis, Photosensitivity, Scarring and milia on hands, among others. Porphyria Cutanea Tarda affects approximately 1 in 10,000 to 25,000 people. Symptoms can range from mild to severe and may vary between individuals.

Trial Friend lists all active clinical trials for Porphyria Cutanea Tarda from ClinicalTrials.gov, with eligibility criteria translated into plain English. Patients can filter by trial phase and recruitment status, search by location, and use the Match Me tool to score trials against their profile. Management focuses on identifying and avoiding precipitating factors while employing phlebotomy or chelation therapy to reduce iron and porphyrin levels. Phlebotomy (removal of 400-500 mL blood every 1-2 weeks until iron stores deplete) effectively reduces porphyrin levels and is first-line therapy for most patients.

As of October 14, 2026, no current FDA drug label names Porphyria Cutanea Tarda as a condition the drug treats.

Porphyria Cutanea Tarda is an acquired condition, not an inherited one. About 80% of cases are sporadic, driven by liver iron, alcohol, hepatitis C, HIV or estrogens; the other 20% carry a heterozygous UROD variant that raises susceptibility but still needs those triggers. The condition affects approximately 1 in 10,000 to 25,000 people.

Eligibility for Porphyria Cutanea Tarda clinical trials depends on factors like age, diagnosis, treatment history, and overall health. Each trial sets its own inclusion and exclusion criteria. Trial Friend translates these requirements from medical language into plain English so patients can review them more easily. The Match Me tool can score your profile against active trials to help identify studies that may be a fit.

Participating in a Porphyria Cutanea Tarda clinical trial typically involves scheduled visits, medical tests, and close monitoring by a research team. Depending on the study phase, you may receive an investigational treatment, a placebo, or the current standard of care. Trials may last from a few weeks to several years. Study participation is voluntary, and you can withdraw at any time.